Monopar Therapeutics Inc. Share-based Payment Arrangement, Expense
Monopar Therapeutics Inc. (MNPR) reported Share-based Payment Arrangement, Expense of $476.21 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2023-05-11
- Monopar Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2023-03-31 was $476.21K, a 4.72% decline year-over-year.
- Monopar Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2022-06-30 was $357.29K, a 0.08% decline year-over-year.
- Monopar Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2022-03-31 was $499.81K, a 35.73% increase year-over-year.
- Monopar Therapeutics Inc. share-based payment arrangement, expense for the quarter ending 2021-09-30 was $392.06K, a 38.19% increase year-over-year.
- Monopar Therapeutics Inc. share-based payment arrangement, expense for fiscal 2022 was $1.64M, a 11.80% increase from fiscal 2021.
- Monopar Therapeutics Inc. share-based payment arrangement, expense for fiscal 2021 was $1.47M, a 11.14% increase from fiscal 2020.
- Monopar Therapeutics Inc. share-based payment arrangement, expense for fiscal 2020 was $1.32M, a 30.63% increase from fiscal 2019.
- Monopar Therapeutics Inc. share-based payment arrangement, expense for fiscal 2019 was $1.01M, a 91.03% increase from fiscal 2018.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2023-03-31 | $476.21K 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $1.64M 10-K · filed 2023-03-23 | |||
| 2022-06-30 | $357.29K 10-Q · filed 2022-08-11 | $857.11K derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2022-03-31 | $499.81K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $1.47M 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $392.06K 10-Q · filed 2022-11-10 | $749.66K derived: sum of 2 quarters · filed 2022-11-10 | $1.12M derived: sum of 3 quarters · filed 2022-11-10 | $1.45M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $357.59K 10-Q · filed 2022-11-10 | $725.83K derived: sum of 2 quarters · filed 2022-11-10 | $1.06M derived: sum of 3 quarters · filed 2022-11-10 | $1.34M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-03-31 | $368.23K 10-Q · filed 2022-11-10 | $699.55K derived: sum of 2 quarters · filed 2022-11-10 | $983.27K derived: sum of 3 quarters · filed 2022-11-10 | $1.35M derived: sum of 4 quarters · filed 2022-11-10 |
| 2020-12-31 | $331.32K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $615.03K derived: sum of 2 quarters · filed 2022-03-24 | $982.39K derived: sum of 3 quarters · filed 2022-03-24 | $1.32M 10-K · filed 2022-03-24 |
| 2020-09-30 | $283.71K 10-Q · filed 2021-11-12 | $651.07K derived: sum of 2 quarters · filed 2021-11-12 | $989.57K 10-Q · filed 2020-11-12 | $1.27M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $367.36K 10-Q · filed 2021-11-12 | $705.86K 10-Q · filed 2020-08-06 | $982.66K derived: sum of 3 quarters · filed 2021-11-12 | $1.23M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-03-31 | $338.50K 10-Q · filed 2021-11-12 | $615.30K derived: sum of 2 quarters · filed 2021-11-12 | $858.26K derived: sum of 3 quarters · filed 2021-11-12 | $1.12M derived: sum of 4 quarters · filed 2021-11-12 |
| 2019-12-31 | $276.81K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $519.76K derived: sum of 2 quarters · filed 2021-03-25 | $777.39K derived: sum of 3 quarters · filed 2021-03-25 | $1.01M 10-K · filed 2021-03-25 |
| 2019-09-30 | $242.96K 10-Q · filed 2020-11-12 | $500.59K derived: sum of 2 quarters · filed 2020-11-12 | $734.37K 10-Q · filed 2020-11-12 | $967.36K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $257.63K 10-Q · filed 2020-11-12 | $491.41K 10-Q · filed 2020-08-06 | $724.40K derived: sum of 3 quarters · filed 2020-11-12 | $817.64K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-03-31 | $233.78K 10-Q · filed 2020-11-12 | $466.77K derived: sum of 2 quarters · filed 2020-11-12 | $560.01K derived: sum of 3 quarters · filed 2020-11-12 | $648.58K derived: sum of 4 quarters · filed 2020-11-12 |
| 2018-12-31 | $232.99K 10-Q · filed 2019-11-12 | $326.24K derived: sum of 2 quarters · filed 2019-11-12 | $414.81K derived: sum of 3 quarters · filed 2019-11-12 | $529.33K 10-K · filed 2020-03-27 |
| 2018-09-30 | $93.24K 10-Q · filed 2019-11-12 | $181.81K derived: sum of 2 quarters · filed 2019-11-12 | $296.34K 10-Q · filed 2019-11-12 | $359.53K derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $88.57K 10-Q · filed 2019-11-12 | $203.10K 10-Q · filed 2019-08-08 | $266.29K derived: sum of 3 quarters · filed 2019-11-12 | $310.21K derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-03-31 | $114.53K 10-Q · filed 2019-11-12 | $177.72K derived: sum of 2 quarters · filed 2019-11-12 | $221.64K derived: sum of 3 quarters · filed 2019-11-12 | $419.73K derived: sum of 4 quarters · filed 2019-11-12 |
| 2017-12-31 | $63.19K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $107.11K derived: sum of 2 quarters · filed 2019-02-26 | $305.20K derived: sum of 3 quarters · filed 2019-02-26 | $305.20K 10-K · filed 2019-02-26 |
| 2017-09-30 | $43.93K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $242.02K derived: sum of 2 quarters · filed 2018-11-09 | $242.02K 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $198.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $198.09K 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | $0.00 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |